China’s first Ad5-nCoV COVID-19 vaccine produced by CanSino Biologics was rolled out on February 25th. It is the only single-dose COVID-19 vaccine given conditional approval for roll out in China. But what is an Ad5-nCoV vaccine? What’s the difference between single-dose vaccine and double-dose vaccines? And will those vaccinated be immune to mutated strains of the virus? To find out more, we’ve invited Dr. Xuefeng Yu, Chairman and CEO of CanSino Biologics Inc.; Prof. John Gong from the University of International Business and Economics; and Dr. Muhammad Munir, Virologist and Lecturer in Biomedicine Health and Medicine at Lancaster University.